|
(Health-NewsWire.Net, October 21, 2021 )
Market Overview
SCID (severe combined immunodeficiency) is a group of rare disorders which occurs by mutations in genes involved in the development and function of infection-fighting immune cells. A detailed medical history and physical examination of the child are usually used to diagnose severe combined immunodeficiency (SCID). To help confirm the diagnosis, additional blood tests, including a total blood cell count, may be ordered.
View full report: https://bit.ly/3vAjkbt
Market Dynamics
The factors driving the global severe combined immunodeficiency (SCID) diagnosis market is the increasing incidence of severe combined immunodeficiency (SCID) disorder and the increased awareness of diagnostic procedures.
Increasing incidence of severe combined immunodeficiency (SCID) disorder is estimated to drive the market
Adenosine deaminase deficiency is extremely rare, affecting just around 1 in 200,000 to 1,000,000 infants worldwide. This disorder causes about 15% of SCID cases. SCID (severe combined immunodeficiency) is a rare genetic condition that causes life-threatening immune system abnormalities.
It's a form of primary immunological symptom. Every year, about 1 in 58,000 newborns in the United States is born with SCID. Severe combined immunodeficiency is an inherited primary immunodeficiency disease (PIDD) that often manifests in childhood and causes substantial immune insufficiency, resulting in a weakened immune system that cannot fight off even minor infections. It is thought to be the most serious of the PIDs.
SCID is caused by genetic mutations that alter T cell activity. B cells and NK cells may be altered depending on the type of SCID. These cells play a vital part in the immune system's fight against infection-causing bacteria, viruses, and fungus.
Without therapy with hematopoietic stem cell transplantation, affected newborns generally die during the first year of life. (HSCT) Newborn screening for SCID can identify infants before they become ill, allowing for a faster transplant process and better post-transplant results. Transplantation performed within the first three months of life has the best chance of success.
SCID comes in a variety of forms. The most prevalent kind is caused by a mutation in an X chromosome gene that only affects males. Women may have the disorder, but they also have a normal X chromosome. Since the advent of screening for SCID, recessive versions of the condition, which can afflict both males and girls, have become more common.
A lack of the enzyme adenosine deaminase and a range of other genetic abnormalities produce other kinds of SCID. Infants with SCID are susceptible to common diseases observed in healthy babies. Still, they are also more sensitive to infections caused by organisms or live vaccinations, which are normally not dangerous to children with normal immunity.
Market Segmentation
Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - By Disease Type
X-linked SCID
ADA-SCID
Others
Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - By Test type
TREC
Complete blood count (CBC)
Genetic Test
Biochemical Test
Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - By End-User
Hospitals
Ambulatory Surgical Centers
Other
Global Severe Combined Immunodeficiency (SCID) Diagnosis Market - By Region
North America
Europe
South America
Asia Pacific
Middle East and Africa
Download free sample: https://bit.ly/3B1J4P5
Competitive Landscape
Some major key players in the global severe combined immunodeficiency (SCID) diagnosis market are Archimedlife, PerkinElmer, Health Research, Inc., Winfertility, Portea Medical, LaCAR MDx, Labsystems Diagnostics, Devyser, Revcovi and Leadiant Biosciences, Inc.
The global severe combined immunodeficiency (SCID) diagnosis market is moderately competitive with the limited disorder diagnosis and procedures available.
Topic's you may be interested, Urinalysis Testing Products Market, Allergy Diagnostics Market, Systemic Lupus Erythematosus Market, Systemic Sclerosis Market, Immunosuppressants Drugs Market
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
|
